key: cord-0988531-hlm2eg0t
authors: Niessen, W.M.A.
title: Tandem mass spectrometry of small-molecule antiviral drugs: 3. antiviral agents against herpes, influenza and other viral infections
date: 2020-06-13
journal: Int J Mass Spectrom
DOI: 10.1016/j.ijms.2020.116377
sha: 0a5380a3145cb4326fbc380c33cf6c67e9e7eea8
doc_id: 988531
cord_uid: hlm2eg0t

For the treatment of various viral infections, antiviral drugs may be used. Liquid chromatography–mass spectrometry (LC–MS) with tandem mass spectrometry (MS–MS) operated in selected-reaction monitoring (SRM) mode is the method of choice in quantitative bioanalysis of drugs, e.g., to establish bioavailability, to study pharmacokinetics, and later on possibly for therapeutic drug monitoring. In this study, the fragmentation in MS–MS of small-molecule antiviral drugs against herpes and influenza viruses is reviewed. In this way, insight is gained on the identity of the product ions used in SRM. Fragmentation schemes of antiviral agents are also relevant in the identification of drug metabolites or (forced) degradation products. As information of the fragmentation of antiviral drugs in MS–MS and the identity of the product ions is very much scattered in the scientific literature, it was decided to collect this information and to review it. In this third study, attention is paid to small-molecule antiviral agents used against herpes and influenza virus infections. In addition, some attention is paid to broad-spectrum antiviral agents, that are investigated with respect to their efficacy in challenging virus infections of this century, e.g., involving Ebola, Zika and corona viruses, like SARS-CoV-2, which is causing a world-wide pandemic at this very moment. The review provides fragmentation schemes of ca. 35 antiviral agents. The identity of the product ions used in SRM, i.e., elemental composition and accurate-m/z, is tabulated, and more detailed fragmentation schemes are provided.

In the third part of this series of review papers (see [1] [2] for previous parts), attention is paid to the fragmentation in MS-MS of antiviral agents for herpes and influenza viruses. Thus, structures of relevant compounds were searched on the internet. Subsequently, data on product ions used in selected-reaction monitoring (SRM) for quantitative bioanalysis and MS-MS spectra of these compounds were collected and interpreted. This information is provided in the text below.

Human herpes viruses comprise a large family of viruses, containing double-stranded DNA, some of which are widespread among humans [3] . Clinical manifestation of viral infection vary widely. The herpes family is divided in three subfamilies: α-, β-, and γ-Herpesvirinae. The α-class includes the Herpes simplex viruses type 1 and 2 (HSV-1 and HSV-2) and the varicella zoster virus (VZV; the cause of chickenpox). The β-class includes the human cytomegalovirus (CMV), the human herpes virus 6 (HHV6), and human herpes virus 7. The γ-class includes the Epstein-Barr virus (EBV), the human herpes virus 4, and Kaposi's sarcoma-associated herpes virus (KSHV; HHV8). A variety of compounds are licensed for use as antiviral agents or are currently under development. Most of these compounds are nucleoside analogues.

There are several types of the influenza virus that affect humans [4] [5] . Influenza A and B viruses contain negative-sense single-stranded RNA. Usually, the virus is spread through the air by aerosols from coughs or sneezes. Influenza spreads around the world in yearly outbreaks, which differ in severity, generally with a substantial number of deaths. Larger outbreaks of pandemic nature are less frequent. Well-known influenza pandemics, all related to the Influenza A virus, are the Spanish influenza (H1N1) in 1918, the Asian influenza (H2N2) in 1957, the Hong Kong influenza (H3N2) in 1968, and the Mexican influenza (H7N9) in 2018. Influenza may also affect animals like pigs and birds, e.g. the outbreak of bird flu (H5N1) in 2004. Influenza vaccines are available, but not always successful due to mutations in the virus. The most common treatment of influenza is the use of acetaminophen to relieve fever and muscle pain associated with the disease. There are two classes of antiviral drugs used against influenza, the antagonists of the influenza virus A Matrix-2 proton channel (adamantane derivatives) and the neuraminidase (sialidase) inhibitors (oseltamivir, zanamivir, laninamivir and peramivir).

A multiresidue analysis of 14 anti-influenza and anti-herpes drugs in chicken muscle has been reported [6] . The analytes included anti-influenza drugs (amantadine, rimantadine, oseltamivir, oseltamivir carboxylate, memantine, arbidol, and moroxydine), anti-herpes drugs (acyclovir, ganciclovir, famciclovir, penciclovir, ribavirin and its main metabolite TCONH2), and an immunomodulator (imiquimod). Other multiresidue studies of antiviral agents in chicken meat have been reported as well [7] [8] .

The methods used to collect and interpret data in this study are identical to the ones used in the previous study on the HIV-related antivirals; the description of these are not repeated here [1] .

During the preparation of these review papers, starting in October 2019, the world was struck by a pandemic due to a new corona virus, the so-called severe acute respiratory syndrome (SARS) corona virus 2 (SARS-CoV-2). Therefore, a short section was added at the end of this third part.

The m/z data to interpret the fragmentation in MS-MS, to derive elemental composition and accurate-m/z for the product ions used in SRM and to develop the fragmentation schemes, have been collected by searching the literature using the PubMed search website with search terms like "compound name MS" or "compound name metabolites". The papers found in this way were screened for relevant MS-MS data, i.e., MS-MS spectra, (tabulated) m/z-values for SRM transitions, and, when available, structure proposals for the product ions. Special attention was paid to finding accurate-m/z data, mostly from literature dealing with identification of metabolites or (forced) degradation products. For some compounds, accurate-m/z data were available in an available MS-MS spectral library for toxicological unknown screening [9] .

Generally, the interpretation of the MS-MS spectra is initially performed using nominal m/z values of the product ions, based on logical neutral losses from the structure of the compound [10] . No software tools were applied other than a structure drawing software (ACD/ChemSketch software; version 2018.1.1; www.acdlabs.com), which was set to automatically calculate exact-m/z values. The elemental compositions and exact-m/z values of the proposed structures are then verified against and/or confirmed by the accurate-m/z data. If in this way no structure proposal is reached for a particular product ion, the process is reversed: a plausible structure proposal is derived from elemental compositions calculated from the accurate-m/z data. Accurate-m/z data of product ions can be used to calculate their possible elemental composition. Such calculations were performed using a ±3 mDa window, which generally (but not always) is appropriate to the available data. With respect to the product ions in an MS-MS spectrum, the elemental composition of a product ion is restricted by the elemental composition of the precursor ion (except in some rare, specific cases, when ion-trap instruments are used [11] ). This greatly reduces the number of possible hits. Thus, the proposed structures of the product ions have been evaluated, at least in terms of elemental composition and logical neutral losses [10] . Whenever needed, names of product ions or neutral losses were generated with the "Generate Name for Structure" option available in the ACD/ChemSketch software. If the elemental composition derived from available accurate-m/z data is not in agreement with the elemental composition of the literature-proposed structure of a product ion, alternative structures are proposed for such product ions; this discrepancies have been discussed in the text.

Throughout the text, the m/z values, when expressed as accurate-m/z (measured) or exact-m/z (calculated), are given with three significant digits. With the current mass accuracy of typically 1-3 ppm of high-resolution MS instruments and ions with m/z below 1000, the error is in the third decimal place. As SRM transitions in the Tables have been acquired on different instruments from various manufacturers, it was decided not to add information on the collision energy applied, as a particular set collision energy value may yield different levels of fragmentation between instruments from different manufacturers. It must be added, that information on the applied collision energy in SRM and/or MS-MS spectrum acquisition is often missing in the literature studied for this review.

In this section, the MS-MS fragmentation of the antiviral agents against Herpes viruses is reviewed. As ribavirin is also used in HCV treatment, it was already discussed in Part 2 [2] . Characteristic SRM transition used in their analysis in biological matrices are collected in Table 1 ; its fragmentation scheme can be found elsewhere [2] . Some compounds are analyzed in the positive-ion mode (Table 1a) , some others in negative-ion mode (Table 1b) , whereas a few compounds can be analyzed in either positive-ion or negative-ion mode. No LC-MS data were found for foscarnet. 

Most acyclic nucleoside analogues used in against Herpes viruses are guanine-related compounds. Aciclovir 

Two other compounds under development as Herpes antivirals are letermovir, targeted at CMV infections, and pritelivir, an antiviral helicase-primase inhibitor. Limited information of MS-MS behavior is available. 

In this section, the MS-MS fragmentation of the antiviral agents against influenza viruses is reviewed. There are two classes of antiviral drugs used against influenza, the antagonists of the influenza virus A Matrix-2 proton channel (adamantane derivatives) and the neuraminidase (sialidase) inhibitors (oseltamivir, zanamivir, laninamivir and peramivir). All compounds are analyzed in positive-ion mode. Characteristic SRM transition used in their analysis in biological matrices are collected in Table 2 . 

Amantadine and rimantadine are inhibitors of the Matrix-2 protein, a proton-selective viroporin, integral in the viral envelope of the influenza A virus. They used against influenza A, but because of their antagonistic properties to the N-methyl-D-aspartate receptor (NMDAR), they are also used in the treatment of parkinsonism, and multiple sclerosis (like the structural analogue memantine). In order to prevent potential resistance issues in human, the use of amantadine and rimantadine as antiviral agents during poultry farming has been banned in many countries. Therefore, sensitive methods for the analysis of these antiviral agents in chicken muscle tissues are needed [33] [34] . (Figure 4 ) [46] . The identity of these product ions has been confirmed by accurate-m/z data [9] . 

The initial fragmentation of the neuraminidase inhibitors laninamivir, peramivir, and zanamivir is the loss of 59 Da, which can either involve the loss of guanidine (CH 5 N 3 ) or of acetamide (C 2 H 5 NO), and the formation of the protonated guanidine with m/z 60 ([CH 6 N 3 ] + ) or protonated acetamide with m/z 60 ([C 2 H 6 NO] + ). Fragmentation of [ 13 C 1 15 N 2 ]-zanamivir (labeling at the guanidine moiety, as indicated with * in Figure 6 ) indicates the loss of guanidine [43] , as also confirmed by accurate-m/z data, available for zanamivir [47] . Either the ion with m/z 60 or the product ion resulting from the loss of guanidine is generally used in SRM. Thus The fragmentation of zanamivir is studied in detail in the course of an environmental photodegradation study [47] . Zanamivir ([M+H] + with m/z 333) shows a product ion with m/z 274 due to the loss of guanidine (CH 5 N 3 ); the protonated guanidine with m/z 60 is also observed. The ion with m/z 274 shows subsequent fragmentation to m/z 215 due to the loss of acetamide (C 2 H 5 NO), which in turn shows three consecutive water losses to the ions with m/z 197, 179, and 151. Alternatively, the ion with m/z 274 shows consecutive losses of water, ethenone (C 2 H 2 O), ammonia (NH 3 ), formaldehyde (CH 2 O), and formic acid (CH 2 O 2 ) to the ions with m/z 256, 214, 197, 167, and 121, respectively ( Figure 6 ). The elemental compositions of the product ions in confirmed by accurate-m/z data [47] . 

Umifenovir (arbidol) is only approved for use against influenza in Russia and China. It inhibits membrane fusion, and thereby prevents contact between the virus and target host cells. Umifenovir ([M+H] + with m/z 477) shows product ions with m/z 432 due to the loss of dimethylamine ((H 3 C) 2 NH), with m/z 387 due to the subsequent loss of ethanal (C 2 H 4 O), with m/z 323 due to the loss of dimethylamine and a phenylsulfanyl radical (C 6 H 5 S • ), with m/z 294 and with m/z 279 due to the subsequent loss of an ethyl radical ( • C 2 H 5 ) or ethanal, respectively (Figure 7) . The fragmentation is confirmed by accurate-m/z data, acquired in the course of a metabolite identification study [49] .

Moroxydine ([M+H] + with m/z 172) shows extensive fragmentation in the guanidine substituent of the molecule, that is product ions with m/z 155 due to the loss of NH 3 , with m/z 130 due to the loss of methanediimine (CH 2 N 2 ), with m/z 113, which is protonated N-cyanomorpholine 

During the first 20 years of the 21th century, several outbreaks of virus infections took place, causing serious health problems, e.g., the severe acute respiratory syndrome ( The epidemic was halted in 2003 by a highly effective global public health response, and SARS-CoV is currently not circulating in humans [50] .

During the preparation of these review papers, a new SARS-CoV-2 was discovered in the city of Wuhan in China in December 2019. This virus, causing the so-called corona virus disease 2019 (Covid- 19) , was found to be extremely contagious. It resulted in a world-wide pandemic. When finishing these reviews (mid April 2020), Covid-19 have caused ca. 2 million confirmed disease cases and more than 120,000 deaths world-wide, whereas when finishing the revision (early June 2020) there were over 6 million confirmed disease cases and more than 375,000 deaths world-wide (https://coronavirus.jhu.edu/map.html). Obviously, this pandemic lead to a boost of research activities towards ways to control the disease and the stop spreading of the virus (more than 18,000 results upon searching NCBI SARS-CoV-2 literature, sequence, and clinical content: https://www.ncbi.nlm.nih.gov/sars-cov-2/). These research activities explore multiple directions, including (1) the search for immunotherapy against the virus, (2) the development of vaccines against the virus, and (3) the search for applicable antiviral agents, e.g., [51] .

In this context, it is interesting to review studies performed earlier in relation to the SARS-CoV outbreak in 2002-2003. Several molecular targets could be considered for discovery and development of antiviral agents [52] , but apparently with little results in terms of new antiviral agents. Therapies for coronaviruses were reviewed, with focus on viral entry inhibitors [53] and on inhibitors of the intracellular life cycle [54] . An extensive overview of drug discovery and therapeutic options against coronaviruses have been complied as well [55] . Candidate therapies against MERS-CoV have also been reviewed [56] , including monoclonal antibodies, antiviral peptides, vaccines, interferons, teicoplanin-derived antibiotics, nucleoside analogues such as 6-mercaptopurine (6MP) and 6-thioguanine (6TG), and protease inhibitors, such as the small-molecule inhibitors camostat, nafamostat, as well as lopinavir and ritonavir, known from HIV treatment. When SARS-CoV and MERS-CoV outbreaks were under control, research funds probably dried out, ignoring the possible occurrence of an outbreak of a similar virus in the future. Hardly any developments on CoV-related antiviral agents has been described.

In the past few months, numerous studies have been reported on possible pharmacotherapeutic treatment for Covid-19 (e.g., [51, [57] [58] [59] [60] ) and many more will follow in the months to come.

In one of these studies [60] , 120 agents were listed and evaluated as possible broad-spectrum antiviral agents (BSAAs). The rationale behind BSAAs is, that different viruses utilize similar pathways and host factors to replicate in the cell. Therefore, compounds that inhibit one of these processes for one virus may do the same for other viruses. This is the drug repurposing approach, which is extremely attractive, because the development of specific drugs for each individual virus will take far too much time. In addition, the safety-in-man assessment of such drugs was already done for their initial therapeutic spectrum. This will (hopefully) greatly facilitate and speed up the approval for their use as antiviral agent.

Among the 120 agents selected as potential BSAAs [60] , drugs from many therapeutic classes are listed, such as anticancer, antibacterial, antiprotozoal drugs, but also immunosuppressants, antidepressants, and anti-arrhythmic and lipid-lowering agents. Whether the compounds listed are actually effective may be a matter of fierce discussion, as for instance demonstrated in the discussion on the effectiveness of the antimalaria drugs chloroquine and hydroxychloroquine in the treatment of Covid-19 [61] . Adequate clinical studies will be necessary.

Among the 120 compound listed as potential BSAAs [60] are actually 27 compounds which are approved or investigated as antiviral agents. In the context of the present review, the focus is on collecting and interpreting available MS-MS data of these 27 antiviral agents. The status of these compounds in this respect is summarized in Table 3 . Table 3 : MS-MS data and interpretation of the 27 antiviral agents, considered as broad-spectrum antiviral agents [60] . ? [68] Favipravir is selectively inhibiting viral RNA-dependent RNA polymerase and is applied as antiviral agent against new influenza strains in Japan. Favipiravir ([M-H]with m/z 156) is analyzed in negative-ion mode. The major product ion with m/z 133 results from the loss of hydrogen isocyanate (HNCO). The product ion with m/z 66 is not understood.

Lobucavir ([M+H] + with m/z 266) is a nucleoside analogue with broad-spectrum activity. It is analyzed in SRM using the product ion with m/z 152, which is the protonated guanine and due to the loss of guanine N 9 -substituent. Camostat and nafamostat were not listed as BSAAs, but as these serine protease inhibitors have been suggested as possible antiviral agents against MERS-CoV [56] , their fragmentation is also discussed here.

The fragmentation of camostat and two of its metabolites (GBPA and GBA) has been reported [69] . Camostat (C 20 

The primary fragmentation of protonated molecules [M+H] + involves backbone cleavages of Cheteroatom (N, O, S) bonds via either an inductive cleavage or a four-center H-rearrangement. Such bonds can often we considered to be the "weak links" in the protonated molecule. However, there are a lot of subtle issues involved in this, which unfortunately may be sometimes obscured a little by the level of detail in the available data.

A nice example of this is the fragmentation of compounds with a guanidine moiety. There are a number of such compounds in the current data set, that is peramivir, zanamivir, moroxydine, camostat, its metabolite GBPA, and nafamostat. In principle, one may expect fragmentation involving the loss of ammonia (NH 3 , [M+H-17] + ), methanediimine (CH 2 N 2 , [M+H-42] + ) and/or guanidine (CH 5 N 3 , [M+H-59] -), as for instance shown for moroxydine (Figure 7) . According to the rule of Field [71] , complementary ions may be observed, that is protonated ammonia ([NH 4 ] + with m/z 18), methanediimine ([CH 3 N 3 ] + with m/z 43) and guanidine ([CH 6 N 3 ] + with m/z 60); the first two ions are generally outside the m/z range the spectrum is acquired with. The formation of the protonated guanidine requires a H-rearrangement to the guanidine moiety. In most cases, a β-H-rearrangement, i.e., a 1,2-elimination, is considered [72] , but the situation is probably more complicated [10] . This implies that the ion with m/z 60 and/or the loss of guanidine is readily observed, if such a Hrearrangement is possible, that is when the guanidine is attached to an aliphatic system, such as with peramivir, zanamivir and moroxydine (Figures 6 and 7) . On the other hand, it will not (or with much lower ion abundance, as it should be formally explained) occur, if such a H-rearrangement is less likely, that is when the group is attached to an aromatic system, such as with camostat, GBPA, and nafamostat ( Figure 9 ). In that case, the loss of methanediimine in observed instead.

The same issues play a role in the fragmentation of amines and ethers. In the di-aliphatic ether, cleavage of either of the two C-O bonds may be observed, as for instance with oseltamivir, whereas in the aliphatic-aromatic ether, there is a preference for the cleavage of the aliphatic-C-O bond rather than the aromatic-C-O bond, as for instance observed in tilorone ( Figure 9 ). In this context, it must be pointed out that the ion with m/z 135 ([C 8 H 7 O 2 ] + ) for GBPA ( Figure 9 ) should actually be considered as the 2-(4-hydroxyphenyl)-1-oxoeth-1-ylium ion ([HO-C 6 H 4 -CH 2 -C≡O] + ) rather than as the 4-(carboxymethyl)phen-1-ylium ion ([C 6 H 4 -CH 2 -COOH] + ); both alternatives are shown in Figure 9 .

In some cases, the fragmentation can be considered as a series of small neutral losses. A illustrative examples is the fragmentation of zanamivir ( Figure 6) .

In yet other cases, the identity of the product ions in terms of elemental composition is clear, but it is more difficult to indicate how such product ions are formed and/or which C-atoms are involved in their generation. This is for instance the case for amantadine and rimantadine (Figure 4) . The choices made in proposing structures for their product ions is primary based on the fact that cleavages at tertiary (and quaternary) C-atoms are more likely to occur, as the positive charge is more stabilized on these sites.

In this way, a wealth of more generally applicable fragmentation rules can be derived from this type of data sets.

The fragmentation of even-electron ions, like protonated molecules [M+H] + , should comply with the even-electron rule [10, [73] [74] . Therefore, the observation of odd-electron product ions immediately attracts attention. In the current set of compounds, only one shows clearly detectable odd-electron ions. It should be noted, that quite often low-abundant odd-electron "satellite" ions are observed next to the (far) more abundant even-electron ions, that are mentioned in the text. In a number of cases, the occurrence of odd-electron product ions can be predicted from the presence of specific functional groups [1] . After the loss of dimethylamine to the ion with m/z 432, umifenovir ( Figure 7) shows an odd-electron ion with m/z 323 ([C 14 H 14 BrNO 3 ] + ) due to the loss of a phenylsulfanyl radical (C 6 H 5 S • ). Sulfur-containing compounds are prone to facilitate radical losses involving the sulfur-containing group. The resulting odd-electron ion may show either the loss of a radical to "return" to an even-electron ion, that is an ethyl radical ( • C 2 H 5 ) to an ion with m/z 294 ([C 12 H 9 BrNO 3 ] + ), or the loss of a neutral molecule to "continue" as an odd-electron ion, that is ethanal (C 2 H 4 O) to an ion with m/z 279 ([C 12 H 10 BrNO 2 ] +• ).

The fragmentation in MS-MS of some 30 antiviral agents involved in the treatment of Herpes and influenza infections has been reviewed. MS-MS spectra and SRM transitions were collected and interpreted. For some compounds, confirmation of the interpretation by accurate-m/z data is required. In addition, available MS information on some BSAAs, which were not yet discussed in these review papers, is reviewed as well.

In order to facilitating the access to the information collected in these review papers, a Supplementary File was complied that alphabetically combines all information on SRM transitions for all 112 compounds discussed in the three parts of this review series (antiviral agents as well as some metabolites and anabolites) in two Tables (one for positive-ion data and one for negative ion data).

The ion with m/z 113 shows secondary fragmentation involving the loss of ethanal (H 3 CCHO) to the 2-(cyanoamino)eth-1-ylium ion with m/z 69

Tandem mass spectrometry of small-molecule antiviral drugs: 1. HIVrelated antivirals

Tandem mass spectrometry of small-molecule antiviral drugs: 2. Hepatitis-related antivirals

Antiviral therapies for herpesviruses: current agents and new directions

Simultaneous determination of 14 antiviral drugs and relevant metabolites in chicken muscle by UPLC-MS/MS after QuEChERS preparation

Simultaneous determination of antiviral drugs in chicken tissues by ultra-high performance liquid chromatography with tandem mass spectrometry

Chromatography column comparison and rapid pretreatment for the simultaneous analysis of amantadine, rimantadine, acyclovir, ribavirin, and moroxydine in chicken muscle by ultra-high performance liquid chromatography and tandem mass spectrometry

Agilent forensic toxicology LC/MS personal compound database and library

Interpretation of MS-MS mass spectra of drugs and pesticides

Solvation of acylium fragment ions in electrospray ionization quadrupole ion trap and Fourier transform ion cyclotron resonance mass spectrometry

Hydrophilic interaction liquid chromatography/electrospray mass spectrometry determination of acyclovir in pregnant rat plasma and tissues

Determination of acyclovir in horse plasma and body fluids by high-performance liquid chromatography combined with fluorescence detection and heated electrospray ionization tandem mass spectrometry

Determination of valganciclovir and ganciclovir in human plasma by liquid chromatography tandem mass spectrometric detection

Determination of cidofovir in human plasma after low dose drug administration using highperformance liquid chromatography-tandem mass spectrometry

Validation of an assay for quantifying ganciclovir in dried blood spots

A sensitive assay for simultaneous determination of plasma concentrations of valganciclovir and its active metabolite ganciclovir by LC/MS/MS

Collisionally-induced dissociation of substituted pyrimidine antiviral agents: mechanisms of ion formation using gas phase hydrogen/deuterium exchange and electrospray ionization tandem mass spectrometry

Development and validation of a LC-MS/MS method for the determination of letermovir in sprague dawley rat plasma and its application to pharmacokinetic study

Development and validation of a high-performance liquid chromatography-tandem mass spectrometry for the determination of penciclovir in human plasma: application to a bioequivalence study

Determination of penciclovir in human plasma by liquid chromatography-electrospray ionization tandem mass spectrometry: application to a clinical pharmacokinetic study

Pharmacokinetics-pharmacodynamics of the helicaseprimase inhibitor pritelivir following treatment of wild-type or pritelivir-resistant virus infection in a murine herpes simplex virus 1 infection model

Efficacy of pritelivir and acyclovir in the treatment of herpes simplex virus infections in a mouse model of herpes simplex encephalitis

Specific, sensitive and accurate liquid chromatographic-tandem mass spectrometric method for the measurement of ribavirin in rat and monkey plasma

Evaluation of a rapid method for the simultaneous quantification of ribavirin, sofosbuvir and its metabolite in rat plasma by UPLC-MS/MS

Stability evaluation and sensitive determination of antiviral drug, valacyclovir and its metabolite acyclovir in human plasma by a rapid liquid chromatography-tandem mass spectrometry method

Collision-induced dissociation of purine antiviral agents: mechanisms of ion formation using gas-phase Hydrogen/Deuterium exchange and electrospray ionization tandem mass spectrometry

Absorption, metabolism, and excretion of [ 14 C]viramidine in humans

LC-MS-MS quantitative determination of brivudine in human plasma and its application to pharmacokinetic studies

Quantification of cidofovir in human serum by LC-MS/MS for children

Amino acid ester prodrugs of nucleoside and nucleotide antivirals

Determination of serum amantadine by liquid chromatography-tandem mass spectrometry

Simultaneous determination of amantadine, rimantadine and memantine in chicken muscle using multi-walled carbon nanotubes as a reversed-dispersive solid phase extraction sorbent

Simultaneous determination of antibiotics and amantadines in animal-derived feedstuffs by ultraperformance liquid chromatographic-tandem mass spectrometry

Clinical pharmacokinetics of laninamivir, a novel long-acting neuraminidase inhibitor, after single and multiple inhaled doses of its prodrug, CS-8958, in healthy male volunteers

Development and validation of a liquid chromatographic-tandem mass spectrometric method for determination of oseltamivir and its metabolite oseltamivir carboxylate in plasma, saliva and urine

Development and validation of a high-throughput zwitterionic hydrophilic interaction liquid chromatography solid-phase extraction-liquid chromatography-tandem mass spectrometry method for determination of the anti-influenza drug peramivir in plasma

In vitro evaluation of absorption characteristics of peramivir for oral delivery

HPLC-MS/MS analysis of peramivir in rat plasma: Elimination of matrix effect using the phospholipid-removal solid-phase extraction method

Quantification of peramivir (a novel antiinfluenza drug) in human plasma by hydrophilic interaction chromatography/tandem mass spectrometry

High-performance liquid chromatography/tandem mass spectrometry method for the determination of arbidol in human plasma

Pharmacokinetics, metabolism, and excretion of the antiviral drug arbidol in humans

Liquid chromatographic-tandem mass spectrometric method for the determination of the neuraminidase inhibitor zanamivir (GG167) in human serum

Determination of zanamivir in rat and monkey plasma by positive ion hydrophilic interaction chromatography (HILIC)/tandem mass spectrometry

Online solid phase extraction liquid chromatography using bonded zwitterionic stationary phases and tandem mass spectrometry for rapid environmental trace analysis of highly polar hydrophilic compounds -Application for the antiviral drug Zanamivir

Analysis of amantadine in Laminaria Japonica and seawater of Daqin Island by ultra-high performance liquid chromatography with positive electrospray ionization tandem mass spectrometry

Evaluation of the phototransformation of the antiviral zanamivir in surface waters through identification of transformation products

ICH guidance in practice: degradation behaviour of oseltamivir phosphate under stress conditions

Metabolite identification of arbidol in human urine by the study of CID fragmentation pathways using HPLC coupled with ion trap mass spectrometry

Antiviral strategies against human coronaviruses

Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases

New antiviral drugs, vaccines and classic public health interventions against SARS coronavirus

Therapies for coronaviruses. Part I of II --viral entry inhibitors

Therapies for coronaviruses. Part 2: Inhibitors of intracellular life cycle

Coronaviruses -drug discovery and therapeutic options

A review of candidate therapies for Middle East respiratory syndrome from a molecular perspective

Compounds with therapeutic potential against novel respiratory 2019 coronavirus

Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review

Review of emerging pharmacotherapy for the treatment of coronavirus disease 2019

Discovery and development of safein-man broad-spectrum antiviral agents

Chloroquine and hydroxychloroquine in covid-19

A sensitive method for the determination of entecavir at picogram per milliliter level in human plasma by solid phase extraction and high-pH LC-MS/MS

A new sensitive method for the simultaneous chromatographic separation and tandem mass spectrometry detection of anticoccidials, including highly polar compounds, in environmental waters

The effect of oral pleconaril on hepatic cytochrome P450 3A activity in healthy adults using intravenous midazolam as a probe

Development and validation of a UHPLC-MS/MS method for quantification of the prodrug remdesivir and its metabolite GS-441524: a tool for clinical pharmacokinetics of SARS-CoV-2/COVID-19 and Ebola virus disease

Simultaneous quantification of tiloronoxim and tilorone in human urine by liquid chromatography-tandem mass spectrometry

Performance of tiloronoxim and tilorone determination in human blood by HPLC-MS/MS: method validation, uncertainty assessment and its application to a pharmacokinetic study

Clinical regimens of favipiravir inhibit zika virus replication in the hollow-fiber infection model

Electrospray ionization tandem mass fragmentation pattern of camostat and its degradation product, 4-(4-guanidinobenzoyloxy)phenylacetic acid

Identification of impurities in nafamostat mesylate using HPLC-IT-TOF/MS: A series of double-charged ions

Chemical Ionization Mass Spectrometry

Unimolecular decompositions of even-electron ions

The 'even-electron' rule

Even-electron ions: a systematic study of the neutral species lost in the dissociation of quasimolecular ions

Tandem mass spectrometry of small-molecule antiviral drugs: 3. Antiviral agents against herpes, influenza and other viral infections W.M.A. Niessen hyphen MassSpec, Margrietstraat 34, 2215 HJ Voorhout, the Netherlands, mail@hyphenms.nl. IJMS_2020_139 Revision Highlights: • Detailed study on the fragmentation of 15 Herpes-related and 9 influenza A-related antiviral drugs in MS-MS

• Tabulated product ions (with elemental composition) used in SRM. • Fragmentation scheme, confirmed using accurate-m/z data. • Broad-spectrum antiviral agents

☒ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.☐The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: